Analyst Price Targets — PRAX
Latest News for PRAX
Baker Bros. Advisors LP added 437,000 shares of Praxis Precision Medicines in the fourth quarter; the estimated transaction value is $81.38 million based on quarterly average pricing.
Perceptive Advisors purchased 431,432 Praxis Precision Medicines shares in the fourth quarter; the estimated trade size was $80.34 million (based on the mean unadjusted close for the quarter). Meanwhile, the quarter-end position value rose by $505.38 million, reflecting both trading activity and stock price appreciation.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.
Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA)
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRAX.
U.S. House Trading
No House trades found for PRAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.